BriaCell Therapeutics (OTCMKTS:BCTXF – Get Rating) is one of 983 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare BriaCell Therapeutics to similar companies based on the strength of its earnings, valuation, institutional ownership, risk, analyst recommendations, profitability and dividends.
This table compares BriaCell Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BriaCell Therapeutics Competitors||-3,315.11%||-198.98%||-37.34%|
Risk & Volatility
BriaCell Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, BriaCell Therapeutics’ peers have a beta of 0.95, suggesting that their average stock price is 5% less volatile than the S&P 500.
Insider and Institutional Ownership
Earnings and Valuation
This table compares BriaCell Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BriaCell Therapeutics||N/A||-$3.68 million||-1.87|
|BriaCell Therapeutics Competitors||$1.86 billion||$248.00 million||-3.25|
BriaCell Therapeutics’ peers have higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations for BriaCell Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BriaCell Therapeutics Competitors||3968||14678||40936||694||2.64|
As a group, “Pharmaceutical Preparations” companies have a potential upside of 118.66%. Given BriaCell Therapeutics’ peers higher possible upside, analysts plainly believe BriaCell Therapeutics has less favorable growth aspects than its peers.
BriaCell Therapeutics peers beat BriaCell Therapeutics on 6 of the 10 factors compared.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.